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Abstract
Background: Gestational diabetes mellitus (GDM) is any degree of impaired glucose tolerance first recognised during
pregnancy. Most women with GDM revert to normal glucose metabolism after delivery of their babies; however, they are at
risk of developing type 2 diabetes later in life as are their offspring. Determining a country’s GDM prevalence can assist with
policy guidelines regarding GDM screening and management, and can highlight areas requiring research. This systematic
review assesses GDM prevalence in Africa.
Methods and Findings: Three electronic databases were searched without language restrictions; PubMed, Scopus and the
Cochrane Library. Thirty-one search terms were searched. Eligible articles defined GDM, stated what GDM screening
approaches were employed and reported GDM prevalence. The reporting quality and risk of bias within each study was
assessed. The PRISMA guidelines for systematic reviews were followed. The literature search identified 466 unique records.
Sixty full text articles were reviewed of which 14 were included in the systematic review. One abstract, for which the full text
article could not be obtained, was also included. Information regarding GDM classification, screening methods and
prevalence was obtained for six African countries; Ethiopia (n = 1), Morocco (n = 1), Mozambique (n = 1), Nigeria (n = 6),
South Africa (n = 4) and Tanzania (n = 1). Prevalence figures ranged from 0% (Tanzania) to 13.9% (Nigeria) with some studies
focussing on women with GDM risk factors. Most studies utilised the two hour 75 g oral glucose tolerance test and applied
the World Health Organization’s diagnostic criteria.
Conclusions: Six countries, equating to 11% of the African continent, were represented in this systematic review. This
indicates how little is known about GDM in Africa and highlights the need for further research. Considering the increasing
public health burden of obesity and type 2 diabetes, it is essential that the extent of GDM is understood in Africa to allow for
effective intervention programmes.
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Introduction
Diabetes mellitus (DM) is a group of conditions that contribute
significantly to the increasing health and financial burden in many
countries around the world [1]. The prevalence of and screening
methods for the clinical subgroups, type 1 diabetes mellitus and
type 2 diabetes mellitus, are relatively well researched and
understood in most countries. However, those pertaining to the
subgroup known as gestational diabetes mellitus (GDM) are less
established [2]. Gestational diabetes mellitus is defined by the
World Health Organization as being ‘‘any degree of glucose
intolerance with onset or first recognition during pregnancy’’ and
should therefore include glucose readings that fall within the
impaired glucose tolerance (IGT) diagnostic range, as well as those
within the diagnostic range for diabetes [3,4]. More recently, the
American Diabetes Association defines GDM as ‘‘diabetes
diagnosed during pregnancy that is not clearly overt diabetes’’ [5].
Pregnancy itself induces changes in maternal glucose metabo-
lism and insulin sensitivity. As pregnancy progresses the demand
for insulin production on the mother’s pancreas increases. In most
instances, pregnant women are able to meet the increased insulin
demand but in some cases these needs are not met resulting in
poor glycaemic control and consequently GDM. Certain factors
including having a family history of diabetes, being over 25 years
of age, being obese, belonging to a particular ethnic group (African
American, Hispanic, Indian) and having previously given birth to
a baby weighing 4 kg or more (macrosomia), put women at greater
risk of developing GDM [6,7].
Pregnancies affected by GDM pose a risk for adversities such as
the need for Caesarean sections due to fetal macrosomia.
Macrosomia occurs as a result of accelerated fetal growth fuelled
by maternal hyperglycaemia [8]. In approximately 95% of GDM
cases maternal glucose metabolism returns to normal after delivery
of the baby [9], however, an association between GDM and the
development of type 2 diabetes mellitus in the mother later in life
exists [10,11]. In addition, research into the long term effects of
poor maternal glucose metabolism on the fetus has revealed that
offspring born to mothers with GDM are susceptible to IGT and
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obesity [12,13]. With these associations in mind it would be
important to identify pregnant women at risk for GDM so that
prevention management such as lifestyle modifications can be
implemented [14].
Consensus regarding screening for and classification of GDM is
yet to be achieved globally [2]. The most recognised diagnostic test
for GDM is the oral glucose tolerance test (OGTT) usually
performed between 24–28 weeks gestation [15]. Different screen-
ing regimes for GDM exist and as a result studies investigating
prevalence of GDM are often diverse in terms of methods
employed, cut-off values used and consequently, results obtained
[16]. Table 1 summarises some of the different screening regimes
and respective glucose cut-off values used to diagnose GDM.
Not only do different testing methods exist but the availability of
GDM screening differs from country to country and even within
countries. Although it would be ideal to screen every pregnant
woman for GDM it is not always feasible from a cost perspective,
particularly in low- or middle-income countries (LMICs). In many
LMICs, and some high income countries, women tend to be
selected for screening only if they fulfil certain GDM risk-
associated criteria [17]. Due to this selective screening process one
may expect the true extent of GDM in such countries to remain
relatively unknown. Furthermore, prevalence rates may be
dependent upon the specificity and sensitivity of the selective
screening process in identifying at- risk women.
The effects of urbanisation have not only had a profound
impact on developing countries’ economies but also on public
health. The transition from rural to urban ways of life is often
associated with changes in eating habits, body mass and
composition, and reduction in physical activity. The movement
towards more Westernised diets involves increased consumption of
fats, sugars and refined carbohydrates. As a result, LMICs are
experiencing a rapid increase in overweight and obesity as well as
non-communicable diseases, such as diabetes, that accompany
such conditions [1,18]. Considering this, the prevalence of GDM
should be increasing too. Reported prevalence figures for GDM in
two high income countries, the United Kingdom and the United
States of America, are 2–3% and 2–10% respectively [17]. A study
that assessed GDM in the south of India, a LMIC, reported a far
greater prevalence of 13.9% [19]. Gestational diabetes mellitus
prevalence estimates for another LMIC, Brazil, are thought to be
7.0–7.6% [17].
Diabetes was essentially unknown in Africa in 1901, yet in 2013
19.8 million people were reportedly living with the condition and
this number is predicted to increase to 41.5 million in 2035
equating to a 109% increase [20]. In Africa, the movement from a
rural lifestyle to a more industrial urbanised way of life is largely
responsible for the evolving problem of chronic diseases, of which
diabetes is a major contributor [21].
The explosion in the prevalence of diabetes undoubtedly
represents a serious public health burden. In addition, it is more
than likely to bring along with it a considerable increase in GDM.
However, with regards to GDM in Africa, the situation appears
relatively unknown. From a cost perspective, many African
countries employ a selective screening approach for GDM and
the estimated percentage of pregnant women screened is unclear
[17]. In order to suggest policy changes regarding screening for
GDM, which will ultimately prevent the effects of GDM on the
mother and her offspring and in turn reduce the financial and
health burden to a country, it is essential that the extent of the
condition is well understood. Therefore, we performed a
systematic search to identify research into diagnostic strategies,
screening approaches and reported GDM prevalence figures on
the African continent.
Methods
Protocol and Registration
This project was not prospectively registered. A protocol was
developed during the planning process.
Information Sources and Search Strategy
The PRISMA guidelines (Checklist S1) for the reporting of
systematic reviews were followed [22]. Two authors (SM and
SAN) independently performed a literature search using three
electronic databases; PubMed, Scopus and the Cochrane Library.
The following search terms and combinations were used:
‘‘gestational diabetes’’ and Africa; ‘‘impaired fasting glucose’’
and pregnancy and Africa; diabetes and pregnancy and Africa;
‘‘impaired glucose tolerance’’ and pregnancy and Africa; ‘‘gesta-
tional diabetes’’ and ‘‘African countries.’’ In addition, the search
terms ‘‘gestational diabetes,’’ together with the names of each
individual country in Africa were used. For example, ‘‘gestational
diabetes’’ and Egypt; ‘‘gestational diabetes’’ and Namibia;
‘‘gestational diabetes’’ and ‘‘South Africa’’ were entered into the
search. The list of all 54 recognised African countries included in
the search can be found in Appendix S1. Finally, ‘‘gestational
diabetes’’ and ‘‘Sub-Saharan Africa’’ were searched for. Where
possible, filters were set for studies pertaining to humans but
articles written in all languages were included. The search was
performed in September 2013. No time limits were set in an
attempt to gather all articles published up until the end of
September 2013. Once duplicate references were removed the
titles and abstracts of the references were screened.
Studies pertaining to African countries that included the
following were considered relevant:
1) Screening methods for GDM
2) Criteria used to diagnose GDM
3) Prevalence of GDM
If an article failed to mention any of the above three points it
was excluded. In addition, studies were excluded if they were:
1) On type 1 and/or type 2 diabetes only
2) Overviews of GDM
3) Editorials
4) Molecular studies
5) Solely on the outcomes and/or problems associated with
macrosomic infants with no reference to GDM prevalence
and screening
6) Focussed on perinatal mortality and congenital abnormality
rates in babies born to mothers with diabetes
7) Solely comparisons of GDM testing regimes
Data Extraction
Full text articles were obtained and reviewed. Data were then
extracted regarding country, region (rural/urban), population
group, sample size, age of pregnant women in the cohort,
gestational age, how the investigators defined GDM, how they
tested for GDM and what GDM prevalence was reported. In
addition, data were also extracted from abstracts that included
how GDM was screened for, what criteria were used and what
prevalence figures were obtained in the study but for which full
text articles could not be obtained.
Gestational Diabetes in Africa
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Assessment of Reporting Quality and Risk of Bias
The reporting quality of each study was assessed using the
Strengthening the Reporting of Observational Studies in Epide-
miology (STROBE) checklist [23] guided by the published
detailed explanation on how to use the checklist [24]. The
combined checklist designed for cohort, case-control and cross-
sectional studies was utilised (Appendix S2). A quality assessment
score out of 22 was determined for each study by assigning a point
per STROBE item addressed. Good/fair quality papers were
categorised as having a score of $14/22 and poor quality papers
were classified as having a score of ,14/22. All studies, regardless
of their STROBE score, were retained in the systematic review.
Bias was assessed using the Risk of Bias Tool for Prevalence
Studies developed by Hoy, Brooks, Woolfe et al., (2012) [25],
adapted specifically for this systematic review (Appendix S3). The
tool consists of ten items which address four areas of bias and an
eleventh item includes a summary risk of bias assessment. The
items assess both external and internal validity. Each study was
rated as having a low, moderate or high risk of bias. Studies were
classified as having a low risk of bias when eight or more of the ten
questions were answered as ‘‘yes (low risk)’’, a moderate risk of bias
when six to seven of the questions were answered as ‘‘yes (low
risk)’’ and a high risk of bias when five or fewer questions were
answered as ‘‘yes (low risk)’’.
Table 1. The different diagnostic criteria available for the diagnosis of gestational diabetes mellitus.
Group/Organisation Screening test Diagnostic criteria: blood glucose level thresholds
American Diabetes Association [5,52] One step: 2 hr 75 g OGTT At least one of the following must be met:
Fasting: $5.1 mmol/l (92 mg/dl)
1 hr: $10.0 mmol/l (180 mg/dl)
2 hr: $8.5 mmol/l (153 mg/dl)
OR Two step: OR
1) 1 hr 50 g (non-fasting) screen If 1 hr: $10.0 mmol/l (180 mg/dl) proceed with step 2
2) 3 hr 100 g OGTT 3 hr: $7.8 mmol/l (140 mg/dl)
Carpenter and Coustan [53] 3 hr 100 g OGTT At least two of the following must be met:
Fasting: $5.3 mmol/l (95.4 mg/dl)
1 hr: $10.0 mmol/l (180 mg/dl)
2 hr: $8.6 mmol/l (154.8 mg/dl)
3 hr: $7.8 mmol/l (140 mg/dl)
Diabetes Pregnancy Study Group (DPSG) of the European
Association for the Study of Diabetes (EASD) [54]
2 hr 75 g OGTT Fasting: .5.2 mmol/l (93.6 mg/dl)
OR
2 hr: .9.0 mmol/l (162 mg/dl)
International Association of Diabetes and Pregnancy Study
Groups (IADPSG) [42]
2 hr 75 g OGTT At least one of the following must be met:
Fasting: $5.1 mmol/l (92 mg/dl)
1 hr: $10.0 mmol/l (180 mg/dl)
2 hr: $8.5 mmol/l (153 mg/dl)
National Diabetes Data Group (NDDG) (1979) [55] 3 hr 100 g OGTT At least two of the following must be met:
Fasting: $5.8 mmol/l (105 mg/dl)
1 hr: $10.6 mmol/l (190 mg/dl)
2 hr: $9.2 mmol/l (165 mg/dl)
3 hr: $8.0 mmol/l (145 mg/dl)
World Health Organization (1985) [56] 2 hr 75 g OGTT Fasting: $7.8 mmol/l (140 mg/dl)
OR
2 hr: $7.8 mmol/l (140 mg/dl)
World Health Organization (1999) [4] 2 hr 75 g OGTT Fasting: $7.0 mmol/l (126 mg/dl)
OR
2 hr: $7.8 mmol/l (140 mg/dl)
World Health Organization (2013) [20] 2 hr 75 g OGTT At least one of the following must be met:
Fasting: 5.1–6.9 mmol/l (92–125 mg/dl)
1 hr: $10.0 mmol/l (180 mg/dl)
2 hr: 8.5–11.0 mmol/l (153–199 mg/dl)
doi:10.1371/journal.pone.0097871.t001
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Results
Study Selection
The three databases searched identified a total of 568 records. A
total of 102 duplicates were removed resulting in 466 unique
records after which 362 records were excluded based on their titles
being considered irrelevant to the search topic. Of the 104
abstracts screened, 67 abstracts were considered to be relevant.
Due to lack of access to the particular journals, despite several
attempts, seven full text articles could not be obtained. After
reviewing the full text articles of 60 of the records, 14 met all the
criteria for the systematic review. In addition, one abstract, for
which the full text article could not be obtained, was also
considered relevant to the systematic review. A French-speaking
colleague read, translated and extracted data from the one article
written in French. Articles that were excluded were those in which
information regarding classification of, diagnostic criteria for and
screening methods for GDM was missing, where methodology was
unclear and where investigations were performed on immigrant
women as opposed to women representative of the local pregnant
population (Figure 1).
Reporting Quality and Risk of Bias
The STROBE scores per study and the risk of bias results are
listed in Table 2. Quality and risk of bias assessments were not
performed on the study for which only an abstract could be
obtained [26] and for the systematic review that provided details
on that one particular study [27]. With regards to reporting quality
and referring to the STROBE checklist (Appendix S2), describing
the study design, sources of bias, statistical methods used and study
limitations were areas where a number of the studies fell short.
Out of the 13 studies that underwent a risk of bias assessment,
four (31%) were considered to have a high risk of bias; five were
classified as having a moderate risk of bias (38%) and four (31%)
were considered to have a low risk of bias.
Study Characteristics
Thirteen original research articles, one systematic review article
and one abstract pertaining to an original research study were
finally included in the systematic review thus totalling 14 African
research studies (Figure 1). The systematic review article [28]
discussed studies in Sub-Saharan Africa and contained suitable
information concerning the study for which only an abstract was
available. The earliest study was published in 1979 and the latest
in 2013, therefore the original individual studies included in the
review involved research spanning 35 years. Overall, information
regarding GDM classification, screening methods and prevalence
was obtained for six African countries; Ethiopia, Morocco,
Mozambique, Nigeria, South Africa and Tanzania. Two of the
14 studies looked at GDM prevalence amongst women with risk
factors (selective screening), another three studies were case control
studies assessing GDM prevalence amongst women at increased
risk for the condition versus women without risk factors, and the
remaining nine studies involved universal GDM screening of
pregnant women. With reference to Table 3:
Ethiopia. Only one study on GDM in rural Ethiopia,
performed over a decade ago, was included. This was a well
reported study with a low risk of bias. The OGTT was utilised as
the diagnostic test based on the WHO 1985 criteria and a GDM
prevalence of 3.7% was reported [29].
Morocco. The one article pertaining to research performed
in urban Morocco was published in 2009 and was written in
French. The authors reported a relatively high prevalence of
GDM; 7.7% using the Carpenter and Coustan’s criteria.
However, the authors stated that all women who tested positive
on a glucose challenge screening test should have then been
referred for an OGTT yet only 40% of these women received an
OGTT. This suggests that the GDM prevalence could actually
have been higher if all women requiring an OGTT were in fact
tested. The authors did report that the GDM prevalence was
similar to the prevalence of type 2 diabetes in that population.
Unfortunately no reference was made to the ethnicity of the study
participants and considering Morocco has several ethnic groups it
is difficult to say who this prevalence figure applies to [30]. In
addition, the risk of potential bias within this study was high.
Mozambique. Only one case control study, of relatively poor
reporting quality and moderate risk of bias, was analysed from
Mozambique. The study was conducted in 2002 in an urban/
suburban setting and the population group was not stated.
Considering the majority of the Mozambican population is black,
it is assumed that the cohort consisted of black females. Authors of
the study reported a GDM prevalence of 11% amongst women
who had late fetal deaths (cases) and 7.3% amongst women who
had delivered live new-borns (controls). The investigators
diagnosed GDM using their own diagnostic criteria which
classified glucose readings for diabetes mellitus and IGT as
GDM [31].
Nigeria. Six Nigerian studies, all on urban populations, were
evaluated. These studies were conducted between the years 2004–
2013 [27,32–36]. Five of the six studies were classified as having
good/fair reporting quality and one was classified as poor. The
risk of bias across the six studies ranged between low, moderate
and high. All the studies used the OGTT as the method to detect
GDM but different glucose concentrations were employed (50 g,
75 g and 100 g) over a time period of one to three hours.
One study focussed solely on determining the prevalence of
GDM amongst women with risk factors which included (i) history
of fetal macrosomia; (ii) maternal obesity; (iii) previous intrauterine
death; (iv) first degree relative with diabetes; (v) glycosuria and (vi)
history of GDM in a previous pregnancy [27]. Another two studies
were case control studies whereby women with risk factors for
GDM [33] or women who had delivered macrosomic babies [34]
were classified as cases, and women without risk factors [33] or
women who had delivered normal weight babies [34] served as the
controls. Prevalence of GDM was higher amongst the cases in
both studies; 6.2% versus 4.6% (utilising the Carpenter and
Coustan’s criteria) [33] and 2.5% versus 1.5% (utilising the
investigators own diagnostic criteria) [34]. However, Kamanu et
al., (2009), who used their own diagnostic criteria as mentioned
above, diagnosed GDM based on a 1 hour 50 g OGTT (.
7.8 mmol/l/140 mg/dl) and only followed up borderline results
with a 75 g 2 hour OGTT [34]. Usually the 50 g glucose load is
referred to as a glucose challenge test and women who test positive
on the challenge test are followed up with a further OGTT. This is
referred to as the two step approach [5]. It is unconventional for a
50 g OGTT to be performed independently as a diagnostic test
and so the results of this study could be questionable.
Excluding the two case-control studies discussed above, the
other four Nigerian studies utilised the WHO diagnostic criteria
(two used the WHO 1985 criteria and two used the WHO 1999
criteria). One of these four studies compared the detection rate of
the three hour 75 g OGTT using the WHO 1985 criteria to the
three hour 100 g OGTT using the NDDG criteria. The 75 g
OGTT with WHO 1985 diagnostic criteria yielded a higher
GDM prevalence (11.6% versus 4.5%). Conversely, this study
found that the incidence of fetal macrosomia was higher (66.7%)
amongst women diagnosed with GDM by the 100 g OGTT using
Gestational Diabetes in Africa
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Figure 1. Flow diagram illustrating the number of included and excluded studies in the systematic review on gestational diabetes
mellitus in Africa.
doi:10.1371/journal.pone.0097871.g001
Gestational Diabetes in Africa
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the NDDG criteria than amongst women diagnosed with GDM by
the 75 g OGTT using the WHO 1985 criteria (23.1%) [32].
South africa. Four South African studies, conducted between
1979 and 2010, were included in the systematic review [37–40].
One study focused predominantly on Indian women [38], two on
black women [39,40] and the other did not state the ethnicity of
the women [37]. The study by Jackson and Coetzee (1979) tested
women for GDM because they had one or more risk factors.
These risk factors included (i) a parent or sibling with diabetes; (ii)
repeated miscarriages; (iii) obesity; (iv) previous macrosomic infant;
(v) glycosuria; (vi) previous hyperglycaemia; (vii) previous infant
with a severe congenital anomaly; (viii) previous perinatal death;
(ix) polyhydramnios and (x) Indian ethnicity. In addition, this
particular study utilised a 2 hour 50 g OGTT and the
investigators’ own diagnostic criteria [37]. A 50 g glucose load is
usually used for the glucose challenge test and an OGTT generally
utilises either 75 g or 100 g of glucose [5]. The glucose load
chosen for an OGTT by the investigators is unusual. However,
this study was performed in 1979 and can therefore be considered
outdated. Optimisation of the OGTT for the diagnosis of GDM
has developed and improved greatly since then.
All but one study employed a two hour OGTT for the diagnosis
of GDM. The one study that did not employ an OGTT was
interestingly the most recent study in South Africa, conducted in
2010, which tested fasting or random blood glucose levels and
referred to an institutional protocol for diagnostic criteria [40].
Ranchod et al., (1991) compared the WHO 1999 criteria and
DSPG of EASD criteria; WHO criteria produced a higher GDM
prevalence (3.8% versus 1.6%) [38]. Overall, the four South
African studies produced GDM prevalence figures ranging from
1.6% to 8.8%.
Tanzania. One study, published in 1991, was included on
GDM prevalence in rural Tanzania [26]. Unfortunately, the full
text article could not be obtained but data was extracted from the
abstract and the review article [28]. This study involved an
OGTT on a small sample of women (n = 189) using the WHO
1985 diagnostic criteria. A prevalence of 0% was determined.
Unfortunately, as the full text article could not be obtain,
reporting quality and risk of bias for this study could not be
assessed.
Discussion
As far as the authors are aware, no other systematic review has
assessed the prevalence of GDM across the African continent. This
systematic review therefore focussed on studies in African
countries that provided details on the GDM screening methods
employed, the diagnostic criteria used and the prevalence figures
obtained.
Africa consists of 54 countries [41] yet only six African
countries, equating to a mere 11%, were represented in this
systematic review. The percentage of countries for which
prevalence figures were found in a systematic review that assessed
GDM in Asia was 26% [42]. Although still low, this regional
representation is better than the one found in the current review.
This highlights the fact that little seems to be known about the
prevalence and potential burden of GDM in African countries.
Before health care policies and guidelines can successfully be
drawn up and implemented, it is important for one to establish the
extent of a particular problem. It is evident that the extent of
GDM in Africa as a whole is not well investigated. Africa has been
plagued with under-nutrition and GDM may not be considered a
public health concern. However, as African countries shift
economically a double burden of under- and over-nutrition
emerges. With the increase in over-nutrition, particularly in
females, GDM may be naively overlooked.
The results of the systematic review illustrate that the majority
of the studies tested for GDM at around 24–28 weeks gestation,
the recommended gestational age for when an OGTT should be
performed [42]. In addition, the most commonly employed
method for GDM screening in Africa is the two hour 75 g
OGTT with glucose reference ranges as stipulated by the WHO
1985 or 1999 diagnostic criteria (Table 3). Two of the reported
studies made comparisons between different diagnostic criteria
and screening methods. One of the Nigerian studies showed that
the two hour 75 g OGTT using the WHO 1985 criteria diagnosed
more than double the amount of women that the 100 g OGTT
Table 2. Reporting quality and risk of bias assessments.
Author STROBE reporting quality score* Overall risk of bias
Seyoum et al., 1999 [29] 18/22 Low
Bouhsain et al., 2009 [30] 16/22 High
Challis et al., 2002 [31] 11/22 Moderate
Olarinoye et al., 2004 [32] 18/22 Low
Adegbola & Ajayi, 2008 [33] 17/22 Moderate
Kamanu et al., 2009 [34] 19/22 High
Kuti et al., 2012 [27] 19/22 Moderate
Anzaku & Musa, 2013 [35] 17/22 Low
Ozumba et al., 2004 [36] 12/22 High
Jackson & Coetzee, 1979 [37] 15/22 Moderate
Ranchod et al., 1991 [38] 16/22 Low
Mamabolo et al., 2006 [39] 18/22 Moderate
Basu et al., 2010 [40] 19/22 High
Swai et al., 1991#[26] Not assessed Not assessed
*Good/fair quality papers were categorised as having a score of $14/22, poor quality papers were classified as having a score of ,14/22.
#As only the abstract was available an assessment of the reporting quality and risk of bias could not be performed.
doi:10.1371/journal.pone.0097871.t002
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using the NDDG criteria [32]. In addition, one of the South
African studies also illustrated a two-fold detection rate using the
1985 WHO criteria versus the DSPG of EASD criteria [38]. Based
on these findings, whether the 75 g OGTT over-diagnoses GDM
in women is debatable and warrants further investigation. This
statement is supported by the authors of the systematic review on
GDM Asia who commented that the choice of diagnostic criteria
greatly affects GDM prevalence [43].
Many lessons have been learnt from the Hyperglycemia and
Adverse Pregnancy Outcomes (HAPO) study which showed that
there is a continuous association between maternal blood glucose
levels below those diagnostic of diabetes, and adverse outcomes,
such as increased neonatal birth weight [44]. As a result of these
findings various groups have reconsidered the diagnostic criteria
for GDM. The IADSPG diagnostic criteria and WHO 2013
diagnostic criteria are not as stringent as some of the other/
previous criteria mainly because only one abnormal value, as
opposed to two, is sufficient to make a diagnosis of GDM (Table 1).
As a result of using the newer criteria it is very likely that the
prevalence of GDM will increase. This has both positive and
negative consequences. For example, more women will be
diagnosed with GDM and receive treatment and management
which in turn will decrease the effects of maternal hyperglycaemia
on the mother and developing fetus. On the other hand, the health
system in a country could become overburdened with GDM
pregnancies, which could impact heavily on a country’s economy
[45]. However, considering the potential adverse pregnancy
outcomes and the long term effects of GDM on mother and
baby, it may be beneficial to the individuals, as well as a country’s
health system and economy, to diagnose and manage more
women than less. None of the studies reported in this systematic
review used the WHO 2013 or IADPSG criteria.
The percentage of women affected with GDM in this review
was as low as 0% in rural Tanzania [26] and as high as 13.9%
amongst urban Nigerian women with risk factors [27]. This
disparity in prevalence is possibly due to the different methodology
and study designs employed across the 14 studies. Without the
availability of a standardised universal screening protocol the
question is raised as to whether or not the prevalence figures that
were obtained through the various studies are in fact true
reflections of the African situation. In addition, with respect to
the discussion above regarding the newer IADSPG and WHO
2013 diagnostic criteria, should the 14 studies reported in this
systematic review have utilised either of the said criteria the GDM
prevalence figures obtained would most likely have been greater.
Two of the studies, one performed in Nigeria and the other in
South Africa, only tested women with risk factors for GDM and
therefore employed the selective screening approach within their
methodology [27,37]. Certain risk factors have indeed been
proven to be very useful in identifying women at risk for GDM;
when BMI is .30 versus ,20 kg/m2 a woman has a three times
greater risk of developing GDM. Ethnicity is also another key
factor for assessing the risk of developing GDM; Asian women are
five times more likely to develop GDM than Caucasian women,
and African-American women are two times more likely to
develop GDM than Caucasian women [2]. The study by Kuti et
al., (2012) in Nigeria reported a high GDM prevalence (13.9%)
amongst these women and the authors found the strongest
associations between the following risk factors and a diagnosis of
GDM: being over 30 years of age (although this was not used as a
risk factor in the sample selection process), having a family history
of diabetes and having previously been diagnosed with GDM [27].
The South African study that tested women with risk factors
produced a much lower prevalence of GDM (3%) but did report a
strong association between glycosuria, previous hyperglycaemia
and having two or more of the listed risk factors with a diagnosis of
GDM [37]. These studies support that certain maternal risk
factors have a high specificity in identifying women at risk of
developing GDM. This selective screening approach may certainly
have an important role in resource-limited settings.
The countries with the most studies pertaining to GDM were
South Africa and Nigeria, which had four and six studies reported
respectively. With particular reference to South Africa, consider-
ing there are 22 million black females living in the country,
representing approximately 80% of the entire female population
[44], two studies on GDM in black women, one in a rural setting
[39] and one in an urban setting [40], involving a total cohort of
approximately 983 women, cannot be considered representative of
the South African GDM scenario. In addition, out of the six
African countries for which GDM prevalence figures were
obtained, only Nigeria and South Africa have reported relatively
recent figures on macrosomia rates. In Nigeria it is thought that
macrosomia accounts for 7.5% [45] to 8.1% [46,47] of births
which ties in with the high GDM prevalence figures of 8.3% [35]
and 13.9% [27] as reported by the two Nigerian studies in this
review. This suggests macrosomia may be a marker for GDM
prevalence. With respect to South Africa, one study conducted on
black patients in urban Soweto reported a 2.3% macrosomia
prevalence [48] but recent unpublished data from the South
African Department of Health indicates a surprisingly low
macrosomia rate of 1.7% [49]. If macrosomia rates are indicative
of GDM rates then it is imperative that research on GDM is
conducted in other African countries. Algeria and Uganda’s
macrosomia prevalence figures are reported as 14.9% and 8.4%
respectively [45], this raises concern regarding their possible GDM
figures.
It is alarming that very little appears to be known about GDM
in African countries. Research studies, such as those listed in this
systematic review, and particularly those that screen all women in
the study cohort for GDM, are exceptionally useful in assessing the
prevalence of the problem. Based on the 14 reported studies
included in the systematic review, if one ignores the prevalence
figures obtained from the two studies that focussed on higher risk
women [27,37] and takes the prevalence of GDM amongst the
control group in the case control studies [31,33,34], and selects the
prevalence figures obtained by the WHO diagnostic criteria as
opposed to those obtained by the NDDG criteria in one study [32]
and the DSPG of EASD criteria in another study [38], the overall
prevalence of GDM in Africa is estimated to be approximately 5%
(60.1/12); approximately two and a half to seventeen times greater
than some high income countries (Denmark (2–3%), the UK (2–
3%) Germany (0.3–0.8%)) [17].
Interestingly, few studies were performed on rural populations.
As a direct consequence of urbanisation it would be expected that
the prevalence of GDM would be higher amongst urban
populations as opposed to rural populations. Out of the four
South African studies (three urban and one rural) the study in rural
Limpopo produced the highest GDM prevalence (8.8%) amongst
a representative sample of local pregnant women [39]. However,
one of the limitations in making comparisons between the rural
and urban studies in this review is the different GDM screening
methods employed and diagnostic criteria used. In addition, some
studies looked at women already at high risk for GDM. Other
limitations to this review include only published studies, as
opposed to grey literature, being searched and roughly one third
of the studies included in the review having a high risk of bias and
another third having a moderate risk of bias.
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This systematic review has illustrated a gap in the knowledge of
GDM in Africa with only 11% of the African continent being
represented. More epidemiological based studies on GDM in
African countries need to be performed in order to provide reliable
information and thus clarity on the extent of GDM. An ideal
scenario would be if one set of diagnostic criteria and one testing
method was employed across the continent in order to produce
comparable data. In addition, comparisons between GDM
prevalence amongst rural and urban populations within a country
should be carried out in order to assess the extent of the effects of
urbanisation on public health.
Understanding and subsequently attempting to curb the
prevalence of GDM in developing countries is imperative for
maternal and child health. As GDM often results in macrosomic
infants, birth trauma and the need for Caesarean sections at
delivery are expected. This is precarious as it impacts both
maternal and child survival during delivery, and places a
significant economic burden on the health system, which in many
African countries is already struggling with limited resources.
Furthermore, for most countries macrosomia appears to have
been overlooked with the justified focus on low birth weight and
small for gestational age statistics. The Developmental Origins of
Health and Disease research describes how the developing fetus is
susceptible to its environment and that certain in utero events can in
fact alter fetal programming and produce different phenotypes.
Low birth weight is representative of poor fetal nutrition and
growth, and has been shown to be associated with a range of
chronic conditions, including type 2 diabetes [50]. However, high
birth weight requires as much consideration as there is evidence to
support that fetal over-nutrition also poses risk for type 2 diabetes
and other chronic conditions later in life [51]. With the emerging
increase in type 2 diabetes and obesity, macrosomia will become
an important factor in maternal and child health and should be
reported on and monitored by the health care system as a marker
for GDM sooner than later.
As Africa continues along its economic and concomitant
urbanisation and lifestyle transitions, the double burden of both
under- and over-nutrition is a cause for concern. Therefore,
epidemiologists, public health specialists, health professionals, and
policy leaders need to place GDM and macrosomia as key
elements in their maternal and child health framework, thus
enabling policies and practice to minimise the risk of maternal
impaired glucose metabolism during pregnancy.
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